

MicroPhage set to sell test in Europe

LONGMONT - MicroPhage Inc. finished its blood-test study and plans to start shipping the test to Europe this month.

Longmont-based MicroPhage's test is an instrument-free test that determines the presence of staphylococcus aureus bacteria as well as whether methicillin can be used to treat the staph infection.

The tests take as little as five hours whereas the standard of care takes up to three days, the company stated in a press release.

In December, MicroPhage announced it obtained the CE mark, which means the European Union approved its safety. It now anticipates having the test approved in the U.S.

"With more than 1,200 samples tested across four major U.S. medical centers, the product seems to have met or passed all of our expectations," Drew Smith, MicroPhage's research and development vice president, said in a statement.

Full results from the study won't be available until later this year.